Related Insights
Blog
Key implications for nonclinical development: FDA guidance on human gene therapy products incorporating human genome editing
Jul 1, 2024
Article
Relyvrio Approval: Lessons Learned
Oct 31, 2022
Podcast
RBQM Podcast Series | Episode 3: Staying within the Guardrails: How to Push the Boundaries in a Highly Regulated Industry
Jun 16, 2022
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Blog
Preparing for the New Era of Hybrid Regulatory Inspections
Jul 11, 2022
Article
EU Orphan Drug Designation – overcoming regulatory challenges
Jul 20, 2022
Video
Cell & Gene Therapies: A Regulatory Update
Jul 22, 2022
Blog
U.S. drug price reform of 2022: What does the Inflation Reduction Act mean for drug manufacturers?
Aug 17, 2022
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Article
Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
Nov 10, 2022
Article
New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle
May 10, 2022
Playbook
Are you using real-world evidence?
Feb 1, 2023